Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Catalent Inc
(NY:
CTLT
)
56.45
-0.03 (-0.05%)
Official Closing Price
Updated: 7:00 PM EDT, Mar 28, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
1,841,407
Open
56.48
Bid (Size)
55.91 (1)
Ask (Size)
57.95 (1)
Prev. Close
56.48
Today's Range
56.38 - 56.76
52wk Range
31.45 - 68.08
Shares Outstanding
170,341,553
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Best Obesity Drug Stock: Eli Lilly, Novo Nordisk, or Viking Therapeutics?
March 26, 2024
All three of these high-flying stocks could have more room to run.
Via
The Motley Fool
Week In Review: Three Multinationals Plan Investments In Southeast Asia Facilities
March 23, 2024
Shanghai WuXi Biologics has broken ground on a $1.4 billion facility in Singapore. Meanwhile, Novo Nordisk announced plans to invest $556 million to expand its Tianjin city production facility.
Via
Talk Markets
Performance
YTD
+25.31%
+25.31%
1 Month
-3.01%
-3.01%
3 Month
+23.96%
+23.96%
6 Month
+23.50%
+23.50%
1 Year
-15.63%
-15.63%
More News
Read More
Did Novo Nordisk Just Get a Jump on Eli Lilly?
March 19, 2024
Via
The Motley Fool
Exposures
Product Safety
The Top 3 Pharma Stocks to Buy in March2024
March 09, 2024
Via
InvestorPlace
Novo Nordisk Sets Timeframe For Its Next-Gen Experimental Obesity Drug
March 08, 2024
Via
Benzinga
(CTLT) - Analyzing Catalent's Short Interest
February 28, 2024
Via
Benzinga
In-Depth Examination Of 5 Analyst Recommendations For Catalent
February 20, 2024
Via
Benzinga
Earnings Outlook For Catalent
February 08, 2024
Via
Benzinga
Catalent Publishes Fifth Annual Corporate Responsibility Report, Highlighting Progress and Reinforcing Long-Term Commitment
March 07, 2024
From
Catalent, Inc.
Via
Business Wire
Escalating Demand for Obesity Drugs Creates Time-Sensitive Race for Eli Lilly, Novo Nordisk
March 06, 2024
Via
Benzinga
Prediction: Eli Lilly and Novo Nordisk Stock Could Just be Getting Started. Here's Why
March 05, 2024
Via
The Motley Fool
Record-High S&P 500 Propels SPY ETF To $500-Billion Milestone, Nvidia Tops $2 Trillion, Broadcom Surpasses Tesla
March 01, 2024
Via
Benzinga
Topics
ETFs
Stocks
Exposures
US Equities
Top Stocks Not Named Nvidia You Need To Know About In 2024: Here's What Investors Think About Them (Wall Street Vs. Reddit)
February 29, 2024
Via
Benzinga
Eli Lilly, Novo Nordisk's Strategies Against New Weight-Loss Drug Competitors
February 26, 2024
Via
Benzinga
CATALENT INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Catalent, Inc. - CTLT
February 16, 2024
From
Kahn Swick & Foti, LLC
Via
Business Wire
S&P 500's surge to new highs: Bull trap hiding in plain sight?
February 15, 2024
Via
MarketBeat
Topics
ETFs
Economy
Stocks
Exposures
Interest Rates
US Equities
Nearly Half Of S&P 500 Stocks Trade Below 50-Day Moving Average: Which One Is The Cheapest?
February 14, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Novo Nordisk, Eli Lilly Stride To Boost Supply Shortage For Newly Found Holy Grail Of Miraculous Weight Loss Drugs
February 12, 2024
Via
Benzinga
Novo Nordisk Is Scaling a Barrier to Growth. Should You Buy Its Stock Now?
February 11, 2024
Via
The Motley Fool
Novo Nordisk Just Gave Investors $16.5 Billion More Reasons to Get Excited
February 10, 2024
Via
The Motley Fool
Catalent, Inc. Reports Second Quarter Fiscal 2024 Results
February 09, 2024
From
Catalent, Inc.
Via
Business Wire
US Stocks Set To Open Higher, Finish Week Stronger Amid Mixed Earnings: Analyst Sees Another Leg-Up Ahead Of Historically Weak March
February 09, 2024
Via
Benzinga
Earnings Scheduled For February 9, 2024
February 09, 2024
Via
Benzinga
The Skinny On Novo Nordisk: Weight-Loss Meds Make Big Pharma A Big Foe For Food Industry
February 08, 2024
Via
Benzinga
Can financial, healthcare, energy stocks rise as rates stay high?
February 08, 2024
Via
MarketBeat
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.